title: Cost-effectiveness study comparing pharmaceutically licensed plasma for transfusion (OctaplasLG®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK.
abstract: This study evaluates the cost-effectiveness of OctaplasLG® (pharmaceutically licensed plasma for transfusion) versus fresh frozen plasma (FFP) in critically ill patients in the UK using a decision-analytic approach. Transfusion with OctaplasLG® resulted in 0.03 quality adjusted life years (QALYs) and 0.03 life years saved compared with FFP. The discounted cost per life year was £949 ($1504), and the discounted cost per QALY saved was £1030 ($1632) with OctaplasLG® in the UK. Based on a higher price of £70 ($111) for OctaplasLG® versus £28.42 ($45.04) for FFP, OctaplasLG® is considered to be cost-effective at a threshold of £30,000 ($47,548) per QALY.
authors.affiliation: Mapi Values, De Molen 84, 3995 AX Houten, The Netherlands. Electronic address: margreet.vaneerd@mapivalues.com.
authors.forename: Margreet C
authors.initials: MC
authors.lastname: van Eerd
authors.affiliation: Mapi Values, De Molen 84, 3995 AX Houten, The Netherlands.
authors.forename: J N
authors.initials: JN
authors.lastname: Mario Ouwens
authors.affiliation: Mapi Values, De Molen 84, 3995 AX Houten, The Netherlands.
authors.forename: Maria A
authors.initials: MA
authors.lastname: de Peuter
mesh_terms: D003362:Cost-Benefit Analysis; D016638:Critical Illness / Q000191:economics / Q000628:therapy*; D006801:Humans; D010949:Plasma; D010951:Plasma Exchange / Q000191:economics / Q000379:methods*; D019057:Quality-Adjusted Life Years; D006113:United Kingdom